PSA Screening for HIM Act

S. 297, the PSA Screening for HIM Act, would amend federal health insurance requirements to eliminate out-of-pocket costs for prostate cancer screening. The bill would require both group health plans and individual health insurance policies to provide coverage for prostate-specific antigen (PSA) screenings without deductibles, copayments, or other cost-sharing requirements for men at highest risk of the disease, particularly those with a family history of prostate cancer.

The bill aims to remove financial barriers that may prevent high-risk men from accessing early detection screening. Supporters argue that early detection of prostate cancer significantly improves survival rates, with nearly 100% survival when caught early. The legislation has bipartisan support and is backed by medical organizations including the American Urological Association and the American Cancer Society, which view it as a way to address health disparities, particularly for Black men who have higher prostate cancer incidence and mortality rates.

The bill is currently under consideration by the Senate Committee on Health, Education, Labor, and Pensions, where hearings were held in March 2026. It has not yet been voted on by the full Senate.